PreCyte Revenue and Competitors
Estimated Revenue & Valuation
- PreCyte's estimated annual revenue is currently $620k per year.
- PreCyte's estimated revenue per employee is $155,000
Employee Data
- PreCyte has 4 Employees.
- PreCyte grew their employee count by -33% last year.
PreCyte's People
| Name | Title | Email/Phone |
|---|---|---|
1 | Principal Data Scientist | Reveal Email/Phone |
2 | Research Scientist Consultant | Reveal Email/Phone |
3 | Consultant | Reveal Email/Phone |
PreCyte Competitors & AlternativesAdd Company
| Competitor Name | Revenue | Number of Employees | Employee Growth | Total Funding | Valuation |
|---|---|---|---|---|---|
#1 | $0.9M | 6 | 0% | N/A | N/A |
#2 | $0.9M | 6 | 0% | N/A | N/A |
#3 | $5.1M | 33 | 6% | N/A | N/A |
#4 | $5.7M | 37 | 42% | N/A | N/A |
#5 | $1.4M | 18 | -10% | N/A | N/A |
#6 | $3.7M | 48 | -21% | $16M | N/A |
#7 | $1.1M | 7 | 0% | N/A | N/A |
#8 | $0.8M | 5 | -81% | N/A | N/A |
#9 | $2.5M | 16 | -27% | N/A | N/A |
#10 | $0.8M | 5 | -17% | N/A | N/A |
What Is PreCyte?
PreCyte is developing the Indicator Cell Assay Platform (iCAP), a broadly applicable and inexpensive platform for blood-based diagnostics that can be used for early detection of disease, and as a companion diagnostic for drug development. The iCAP uses cultured cells as biosensors, capitalizing on the ability of cells to respond differently to signals present in the serum (or other biofluid) from normal or diseased subjects with exquisite sensitivity, as opposed to traditional assays that rely on direct detection of molecules in blood. Our first application is to Alzheimer's Disease
keywords:N/A
N/A
Total Funding
4
Number of Employees
$620k
Revenue (est)
-33%
Employee Growth %
N/A
Valuation
N/A
Accelerator
Other Companies in Seattle
| Company Name | Revenue | Number of Employees | Employee Growth | Total Funding |
|---|---|---|---|---|
#1 | $0.4M | 4 | -33% | N/A |
#2 | $0.1M | 4 | -33% | $2.5M |
#3 | $0.3M | 4 | N/A | N/A |
#4 | $0.3M | 4 | N/A | N/A |
#5 | $0.1M | 4 | 0% | $2.5M |